The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management

Author： Bjegovic Vesna Terzic Zorica Marinkovic Jelena Lalic Nebojsa Sipetic Sandra Laaser Ulrich

ISSN： 1618-7598

Source： The European Journal of Health Economics, Vol.8, Iss.2, 2007-06, pp. : 97-103

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost‐effectiveness of a risk‐based secondary screening programme of type 2 diabetes

DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol. 32, Iss. 7, 2016-10 ,pp. : 710-729

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK

By McEwan Phil Poole Chris D. Tetlow Tony Holmes Paul Currie Craig J.

Current Medical Research and Opinion, Vol. 23, Iss. 1, 2007-02 ,pp. : 21-31

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US

By Lee W.C. Conner C. Hammer M.

Current Medical Research and Opinion, Vol. 27, Iss. 5, 2011-05 ,pp. : 897-906

Informa Healthcare

Access to resources Recommend Favorite

Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US**

By Tunis Sandra L. Minshall Michael E. St. Charles Meaghan Pandya Bhavik J. Baran Robert W.

Current Medical Research and Opinion, Vol. 24, Iss. 11, 2008-11 ,pp. : 3085-3096

Informa Healthcare

Access to resources Recommend Favorite

The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus

DIABETIC MEDICINE, Vol. 32, Iss. 7, 2015-07 ,pp. : 890-898

John Wiley & Sons Inc

Access to resources Recommend Favorite